Cathay International Holdings Ld Update on renewal of Cross Guarantee Agreement (9918B)

TIDMCTI

RNS Number : 9918B

Cathay International Holdings Ld

12 June 2019

Cathay International Holdings Limited ("Cathay" or the "Company")

Update on renewal of Cross Guarantee Agreement

between Jilin Haizi and Lansen's subsidiaries

Hong Kong, 12 June 2019 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, announces its subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), has announced today that, with reference to the proposed renewal of the 2016 cross guarantee agreement (subject to the approval of Lansen's independent shareholders) as announced on 3 May 2019, Lansen requires additional time to finalize the information to be included in the circular relating thereto, it is expected that the date of despatch of the circular to Lansen's shareholders will be postponed to on or before 21 June 2019.

The full text of the Lansen Announcement can be found at http://www3.hkexnews.hk/listedco/listconews/SEHK/2019/0612/LTN20190612663.pdf and will also be made available at the Announcements & Notices section of Lansen's homepage at http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.

- ENDS -

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director) Tel: [phone]

Patrick Sung (Director and Controller)

Consilium Strategic Communications

Mary-Jane Elliott/ Matthew Neal / Lindsey Neville Tel: [phone]

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Group aims to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a PRC specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a PRC inositol manufacturer; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment in Shenzhen. For more information please visit the Company's website: http://www.cathay-intl.com.hk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCSFWFSEFUSEIM

(END) Dow Jones Newswires

June 12, 2019 06:59 ET (10:59 GMT)